UnitedHealthcare CEO Brian Thompson's shooting death sparked public discussion about healthcare industry frustration. The ...
Drug developers are making a new generation of treatments for blood cancers that arise from abnormal B cells by taking ...
Arjun Goyal and Stefan Vitorovic, two of Vida Ventures' three co-founding managing directors, have exited the firm as it ...
Walgreens is reportedly in discussions to sell itself to a private equity firm as the retail pharmacy giant grapples with ...
Ahead of an advisory committee meeting later this week, the FDA revealed that all studies for RSV vaccines in young children ...
Johnson & Johnson and Legend Biotech say their CAR-T therapy Carvykti has the potential to remove all traces of disease from ...
Cardiff Oncology reported positive Phase 2 trial results for onvansertib combination therapy in RAS-mutated metastatic ...
Halia Therapeutics is moving its lead asset into the second part of a mid-stage trial following initial positive data in ...
Pfizer and Arvinas presented interim data showing vepdegestrant combined better with Eli Lilly's Verzenio than with Pfizer's ...
CervoMed’s dementia drug disappoints in Phase 2: The drugmaker’s neflamapimod missed both the primary and key secondary endpoints in a mid-stage trial of 159 patients with dementia with Lewy bodies.
Well before Roche said it would buy out its CAR-T partner Poseida Therapeutics for $1 billion upfront, another undisclosed ...
BioNTech shared survival data from a Phase 1b/2 trial testing BNT327 (PD-L1xVEGF bispecific) plus nab-paclitaxel in ...